AbbVie Shares Slide 0.96% in Two Days as Trading Volume Drops to 115th Rank

AbbVie (ABBV) shares fell 0.86% on June 23, 2025, marking the second consecutive day of decline, with a total decrease of 0.96% over the past two days. The trading volume was $651 million, a significant drop of 69.68% from the previous day, placing it at the 115th position in the daily market rankings.

AbbVie recently announced new data from a Phase 3 head-to-head study, demonstrating that Atogepant (QULIPTA® / AQUIPTA®) achieved superiority across all endpoints compared to other treatments. This positive development in their migraine treatment could potentially boost investor confidence in the company's pipeline and future prospects.

Additionally, AbbVie's investigational once-daily pill showed promising results in lowering A1C levels by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks in adults with type 2 diabetes. This data suggests that AbbVie continues to make strides in developing innovative treatments for chronic conditions, which could drive long-term growth for the company.